NSE: ONESOURCE · 30 October 2026
- Onesource Specialty Pharma has risen 18.79% over 5 trading sessions; today's move is +0.97%.
- The company reported its consolidated financial results for the quarter ended September 30, 2026, posting revenues of ₹5,162 million, up 37% year-on-year, and EBITDA of ₹1,633 million, up 53% year-on-year. Management highlighted that growth was driven by new drug-device combination (DDC) capacity, strong master service agreement execution, and 12 product launches across global markets.
- Trading volume was 1.21 times the 20-day average daily volume.
Onesource Specialty Pharma share price: 18.79% rise over 5 trading sessions
Onesource Specialty Pharma Ltd. (ONESOURCE) moved higher during the trading session, gaining 0.97% to close at ₹1,584.80 compared to its previous close of ₹1,569.60. The stock opened at ₹1,579.00 and moved within an intraday range of a low of ₹1,541.20 and a high of ₹1,598.10.
The broader market and sector environment showed positive momentum, with the benchmark Nifty rising 0.51% and the Nifty Pharma sector gaining 1.55% during the session. Onesource's upward movement of 0.97% is broadly consistent with the supportive sector backdrop, though the stock has experienced notable volatility across shorter timeframes, posting a 5-day return of 18.79% and a 20-day return of 4.15% after prior session pullbacks of -0.51% and -1.27% over the preceding two days.
Company disclosures provide relevant operational context, including a recent regulatory update on October 30, 2026, where the company announced the receipt of the Establishment Inspection Report (EIR) with a 'Voluntary Action Indicated' (VAI) classification from the USFDA for its Sterile Product Division (SPD) facility in Bengaluru. This follows strong Q2FY27 financial results reported on October 27, 2026, which featured a 37% year-on-year increase in revenue to ₹5,162 million and a 53% year-on-year rise in EBITDA to ₹1,633 million, driven by new drug-device combination (DDC) capacity and broader segment execution.
9.52 lakh shares traded by 30 October 2026 · 03:25 PM IST. This compares with a 20-day average daily volume of 7.86 lakh shares (1.21 times). The five-day average daily volume was 25.57 lakh shares. Separately, the NSE report for 29 October 2026 showed 4.63 lakh shares delivered, representing 62.85% of that day’s traded volume. The same report recorded 40,707 trades.
The 0.97% gain aligns with broader Nifty Pharma sector strength (+1.55%) and follows recent substantive disclosures regarding a clean USFDA inspection outcome for the Bengaluru facility and robust Q2FY27 revenue and EBITDA growth.
Latest Company Developments
The company reported its consolidated financial results for the quarter ended September 30, 2026, posting revenues of ₹5,162 million, up 37% year-on-year, and EBITDA of ₹1,633 million, up 53% year-on-year. Management highlighted that growth was driven by new drug-device combination (DDC) capacity, strong master service agreement execution, and 12 product launches across global markets.
Demonstrates robust operating leverage and scaling commercial volumes across key specialty pharmaceutical business segments.
The Board of Directors approved the change in designation of Dr. Claudio Albrecht from Independent Director to Non-Executive Non-Independent Director, subject to shareholder approval, drawing on his extensive three-decade experience in the global generics and pharmaceutical industry.
Realigns board composition and leverages advisory expertise in pharmaceutical acquisitions and strategic investments.
a press release dated October 27, 2026, titled "OneSource Announces Strong Q2FY27 ResultsRevenue up 37% YoY and EBITDA up 53% YoY".
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 13.76% on 30 September 2026. This compares with 12.98% on 30 June 2026, a change of +0.78 percentage points.
The filing reported 25 MF/UTI holders.
What to Watch Next
- Commercial ramp-up and execution of the second DDC cartridge line and upcoming line 3 operations
- Global product launches and regulatory approval progress in regulated markets like Brazil, Turkey, and Canada
- Sustained delivery and cash volume trends relative to the 20-day average volume benchmark
- Biologics customer onboarding progress following recent wins with US biotech partners
Other Dated Coverage
- Onesource Specialty Pharma Share Price Today: Rises 12.36% in 3 Trading Sessions | 29 October 2026 — 29 October 2026
- Onesource Specialty Pharma Share Price Today: Rises 12.90% in 2 Trading Sessions | 28 October 2026 — 28 October 2026
- Onesource Specialty Pharma Share Price Today: Rises 19.41% in 2 Trading Sessions | 27 October 2026 — 27 October 2026
More Onesource Specialty Pharma news and dated analysis →
Frequently Asked Questions
What is the latest Onesource Specialty Pharma company news?
The company reported its consolidated financial results for the quarter ended September 30, 2026, posting revenues of ₹5,162 million, up 37% year-on-year, and EBITDA of ₹1,633 million, up 53% year-on-year. Management highlighted that growth was driven by new drug-device combination (DDC) capacity, strong master service agreement execution, and 12 product launches across global markets.
How strong was Onesource Specialty Pharma’s trading volume?
9.52 lakh shares traded, 1.21 times the 20-day average daily volume. The price and volume data are dated 30 October 2026 · 03:25 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.